Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Patel SA, Kollmeier M, Crook J, Krauss D, Morton G, Chang AJ, Helou J, Hsu IC, Menard C, Patel S, Robin T, Rossi PJ, Zelefsky MJ, Kamrava MR. High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement. Brachytherapy. 2025 Sep-Oct; 24(5):644-662.
-
Lee D, Jeon KH, Jung J, Han K, Cho MH, Cho IY, Shin DW. Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study. Rheumatology (Oxford). 2025 Jun 01; 64(6):3458-3467.
-
De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. Target Oncol. 2025 May; 20(3):503-517.
-
Ganesan V, Steinberg RL, Trivedi H, Sorokin I, Johnson BA, Gahan JC. Scheduled intravenous ketorolac is safe and reduces narcotic use after robotic-assisted simple prostatectomy. J Robot Surg. 2024 Oct 03; 18(1):358.
-
Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, Penney KL, Lotan TL, Abida W, DeArment EG, Lu K, Janas T, Hu S, Vander Heiden MG, Loda M, Boselli M, Amon A, Mucci LA. RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proc Natl Acad Sci U S A. 2024 Sep 03; 121(36):e2405543121.
-
Trinh K, Chow DZ, Park H, Habib U, Offit L, Franquet E, Almeida RR, Wang Y, Borges N, Jamal F, Jacene HA, Heidari P, Ng TSC. Evaluating the Added Value of Concurrent Contrast-enhanced Diagnostic CT for PSMA-PET/CT Interpretation. Acad Radiol. 2025 Jan; 32(1):275-286.
-
Jain V, McIntosh L. Subacute Cerebral Infarct: An Unusual Cause of Radiotracer Uptake at 18 F-PSMA PET/CT. Clin Nucl Med. 2024 Sep 01; 49(9):882-883.
-
de Rooij M, Allen C, Twilt JJ, Thijssen LCP, Asbach P, Barrett T, Brembilla G, Emberton M, Gupta RT, Haider MA, Kasivisvanathan V, L?gager V, Moore CM, Padhani AR, Panebianco V, Puech P, Purysko AS, Renard-Penna R, Richenberg J, Salomon G, Sanguedolce F, Schoots IG, Th?ny HC, Turkbey B, Villeirs G, Walz J, Barentsz J, Giganti F. PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol. 2024 Nov; 34(11):7068-7079.
-
Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, Baroni RH, Briganti A, De Visschere P, Dickinson L, G?mez Rivas J, Haider MA, Kesch C, Loeb S, Macura KJ, Margolis D, Mitra AM, Padhani AR, Panebianco V, Pinto PA, Ploussard G, Puech P, Purysko AS, Radtke JP, Rannikko A, Rastinehad A, Renard-Penna R, Sanguedolce F, Schimm?ller L, Schoots IG, Shariat SF, Schieda N, Tempany CM, Turkbey B, Valerio M, Villers A, Walz J, Barrett T, Giganti F, Moore CM. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol. 2024 Sep; 86(3):240-255.